Andere Sprachen Enliven Therapeutics, Inc.

Aktien

A3DGS0

US29337E1029

ELVN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
23,37 ^USD	-0,34 %		+9,00 %	+68,86 %

27.06.	Enliven Therapeutics Insider verkauft Aktien im Wert von $259.902, laut einer aktuellen SEC Einreichung	MT
11.06.	ENLIVEN THERAPEUTICS, INC. : Baird bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Enliven Therapeutics Insider Sold Shares Worth $259,902, According to a Recent SEC Filing	27.06.
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to S&P Pharmaceuticals Select Industry Index	24.06.
Enliven Therapeutics, Inc. Appoints Lori Kunkel to the Committee	29.05.
Enliven Therapeutics to Present at Two Upcoming Investor Conferences	29.05.
Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing	20.05.
Enliven Therapeutics Q1 Loss Narrows	14.05.
Enliven Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update	14.05.
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	11.04.
Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	11.04.
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors	09.04.
Enliven Therapeutics, Inc. Appoints Lori Kunkel to Board of Directors	09.04.
Enliven Therapeutics, Inc. announced that it has received $90.000014 million in funding	03.04.
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024	28.03.
North American Morning Briefing : Investors -2-	21.03.
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates	19.03.
Enliven Therapeutics, Inc. announced that it expects to receive $90.000014 million in funding	19.03.
Enliven Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	14.03.
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Enliven Therapeutics, Inc.

Aktien

A3DGS0

US29337E1029

ELVN

Andere Sprachen

Filter